Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozarelix acetate for mild to moderate Alzheimer's disease in male patients (130 mg every 4 weeks x3)
2004-005001-29Phase 2Terminated
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Jun 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ozarelix in Alzheimer's disease (AD), sponsored by COSCIENS Biopharma Inc. Primary endpoint: ADAS-cog sum score. Started Jun 2006; status: terminated.
02
Drugs
ozarelix
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2004-005001-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005001-29.